脂蛋白肾病1例报道及文献复习
Lipoprotein Nephropathy: A Case Report and Literature Review
DOI: 10.12677/MD.2019.94017, PDF,   
作者: 杨 琨, 刘佳丽, 李沁芸, 岳燕林, 张和平*:川北医学院附属医院肾病内科,四川 南充
关键词: 脂蛋白肾病APOE病例报告历史文献Lipoprotein Nephropathy APOE Case Report Historical Literature
摘要: 目的:加深对脂蛋白肾病的临床认识。方法:回顾性分析2017年6月川北医学院附属医院肾内科收治1例脂蛋白肾病患者的临床特征、实验室检查指标、诊疗经过及治疗转归,并结合相关文献复习展开讨论。结果:患者,50岁,男性,以反复颜面及双下肢浮肿为主要临床表现,考虑为肾病综合症,给予激素及免疫抑制剂治疗后症状缓解不明显,实验室指标加重,行肾穿刺活检术诊断为脂蛋白肾病,给予调脂、减少尿蛋白、保肾等治疗后,患者浮肿消退,白蛋白、血脂恢复正常范围,肾功能无明显恶化,进入临床随访观察阶段。结论:脂蛋白肾病是一种罕见的遗传性肾脏疾病,发病率低,以不同程度蛋白尿为主要表现,对激素、细胞毒性药物治疗无效,后期多进展为慢性肾功能衰竭,预后差。需引起广大临床医师的重视。
Abstract: Objective: To deepen the clinical understanding of lipoprotein nephropathy. Methods: A case of lipoprotein nephropathy admitted to the Department of Nephrology of the Affiliated Hospital of North Sichuan Medical College in June 2017 was selected. The clinical characteristics, laboratory examination indicators, diagnosis, treatment and transformation and development of the disease were retrospectively analyzed, and discussed with related literature review. Results: The patient was a 50 years old male. Repeated facial and lower extremity edema was the main clinical mani-festation. Nephrotic syndrome was diagnosed. Symptoms were not relieved after treatment with hormones and immunosuppressants. Laboratory indicators were aggravated. Renal biopsy was performed to diagnose lipoprotein nephropathy. After treatment with lipid lowering, urinary protein lowering and kidney protection, edema subsided, albumin and blood lipid returned to normal range, renal function did not deteriorate significantly. He then went into the follow-up ob-servation stage clinically. Conclusion: Lipoprotein nephropathy is a rare hereditary kidney disease with low incidence. It is mainly manifested by proteinuria of different degrees. It has no effect on hormones and cytotoxic drugs. It usually develops into chronic renal failure in later stages and poor prognosis. It needs to attract the attention of clinicians.
文章引用:杨琨, 刘佳丽, 李沁芸, 岳燕林, 张和平. 脂蛋白肾病1例报道及文献复习[J]. 医学诊断, 2019, 9(4): 87-92. https://doi.org/10.12677/MD.2019.94017

参考文献

[1] Liberopoulos, E., Siamopoulos, K. and Elisaf, M. (2004) Apolipoprotein E and Renal Disease. American Journal of Kidney Diseases, 43, 223-233. [Google Scholar] [CrossRef] [PubMed]
[2] Saito, T., Ishigaki, Y., Oikawa, S. and Yamamoto, T.T. (2002) Etiological Significance of Apolipoprotein E Mutations in Lipoprotein Glomerulopathy. Trends in Cardiovascular Medicine, 12, 67-70. [Google Scholar] [CrossRef
[3] Saito, T., et al. (1999) Lipoprotein Glomerulopathy: Renal Lipidosis Induced by Novel Apolipoprotein E Variants. Nephron, 83, 193-201. [Google Scholar] [CrossRef] [PubMed]
[4] 王秋媛. 脂蛋白肾病发病机制研究进展[J]. 国际泌尿系统杂志, 2014, 34(3): 414-419.
[5] Rall Jr., S.C., Weisgraber, K.H. and Mahley, R.W. (1982) The Complete Amino Acid Sequence. The Journal of Biological Chemistry, 257, 4171-4178.
[6] Oikawa, S., Matsunaga, A., Satio, T., et al. (1997) Apolipoprotein E Sendai (Arginine 145 Proline): A New Variant Associated with Lipoprotein Glomerulopathy. Journal of the American Society of Nephrology, 8, 820-823.
[7] 潘永利, 陈育青, 张宏, 等. 四例脂蛋白肾病患者载脂蛋白E基因突变筛查[J]. 中华肾脏病杂志, 2006, 8(1): 449-453.
[8] Wu, H., Yang, Y. and Hu, Z. (2018) The Novel Apolipoprotein E Mutation ApoE Chengdu (c.518T > C, p.L173P) in a Chinese Patient with Lipoprotein Glomerulopathy. Journal of Atherosclerosis and Thrombosis, 25, 733-740. [Google Scholar] [CrossRef] [PubMed]
[9] Kanamaru, Y. (2002) Chronic Graft-versus-Host Autoimmune Disease in Fc Receptor Chain-Deficient Mice Results in Lipoprotein Glomerulopathy. Journal of the American Society of Nephrology, 13, 1527-1533. [Google Scholar] [CrossRef
[10] Miyahara, Y., et al. (2012) Scavenger Receptor Expressions in the Kidneys of Mice with Lipoprotein Glomerulopathy. Clinical and Experimental Nephrology, 16, 115-121. [Google Scholar] [CrossRef] [PubMed]
[11] Zhang, X., Hong, L.Z., Jun, L.S., et al. (2008) Successful Treatment of Patients with Lipoprotein Glomerulopathy by Protein A Immunoadsorption: A Pilot Study. Nephrology Dialysis Transplantation, 24, 864-869. [Google Scholar] [CrossRef] [PubMed]
[12] Andrews, P.A., O’Donnell, P.J., Dilly, S.A., et al. (1997) Recurrence of Lipoprotein Glomerulopathy after Renal Transplantation. Nephrology Dialysis Transplantation, 12, 2442-2444. [Google Scholar] [CrossRef] [PubMed]
[13] Shimizu, M., Ohno, T., Kimoto, H., Hosono, S. and Nozawa, M. (2001) A Newborn Infant with Lipoprotein Glomerulopathy Asso-ciated with Congenital Nephrotic Syndrome. Pediatrics International, 43, 78-80. [Google Scholar] [CrossRef] [PubMed]
[14] Usui, R., Takahashi, M., et al. (2016) Five-Year Fol-low-Up of a Case of Lipoprotein Glomerulopathy with APOE Kyoto Mutation. CEN Case Reports, 5, 148-153. [Google Scholar] [CrossRef] [PubMed]
[15] Hu, Z.X., Huang, S.M., Wu, Y., et al. (2014) Hereditary Features, Treatment, and Prognosis of the Lipoprotein Glomerulopathy in Patients with the APOE Kyoto Mutation. Kidney In-ternational, 85, 416-424. [Google Scholar] [CrossRef] [PubMed]
[16] 杨聚荣, 何娅妮, 林利容, 等. 免疫吸附治疗重症脂蛋白肾病1例报道[J]. 中国血液净化, 2006, 11(5): 816-818.
[17] Li, W., Wang, Y., Han, Z., et al. (2014) Apolipoprotein E Mutation and Double Filtration Plasmapheresis Therapy on a New Chinese Patient with Lipoprotein Glomerulopathy. Kidney and Blood Pressure Research, 39, 330-339. [Google Scholar] [CrossRef] [PubMed]
[18] 晋中恒, 郭术莲, 蒋松, 等. 脂蛋白肾病治验2例[J]. 临床合理用药, 2013, 6(3): 132-133.